Brexit Delays Key ATMP Guideline Update – EMA Says Perhaps Not So Bad
Executive Summary
The European Medicines Agency's proposal to revise its decade-old guideline on safety and efficacy follow-up and risk management of advanced therapies has generated keen interest among stakeholders. The update of this key guideline, however, is on hold due to Brexit.